Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/25083991http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/25083991http://www.w3.org/2000/01/rdf-schema#comment"Despite advancement in breast cancer treatment, 30% of patients with early breast cancers experience relapse with distant metastasis. It is a challenge to identify patients at risk for relapse; therefore, the identification of markers and therapeutic targets for metastatic breast cancers is imperative. Here, we identified DP103 as a biomarker and metastasis-driving oncogene in human breast cancers and determined that DP103 elevates matrix metallopeptidase 9 (MMP9) levels, which are associated with metastasis and invasion through activation of NF-κB. In turn, NF-κB signaling positively activated DP103 expression. Furthermore, DP103 enhanced TGF-β-activated kinase-1 (TAK1) phosphorylation of NF-κB-activating IκB kinase 2 (IKK2), leading to increased NF-κB activity. Reduction of DP103 expression in invasive breast cancer cells reduced phosphorylation of IKK2, abrogated NF-κB-mediated MMP9 expression, and impeded metastasis in a murine xenograft model. In breast cancer patient tissues, elevated levels of DP103 correlated with enhanced MMP9, reduced overall survival, and reduced survival after relapse. Together, these data indicate that a positive DP103/NF-κB feedback loop promotes constitutive NF-κB activation in invasive breast cancers and activation of this pathway is linked to cancer progression and the acquisition of chemotherapy resistance. Furthermore, our results suggest that DP103 has potential as a therapeutic target for breast cancer treatment."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.org/dc/terms/identifier"doi:10.1172/jci73451"xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Lee M.H."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Sun W."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Zeng Q."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Tan P."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Wu Z."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Kong X."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Lim Y.P."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Miyamoto S."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Zhu T."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Hui K.M."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Thiery J.P."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Miller L.D."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Lim C.T."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Lobie P.E."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Kumar A.P."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Tergaonkar V."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Salto-Tellez M."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Tan P.H."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Yap C.T."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Shin E.M."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Lim S.W."xsd:string
http://purl.uniprot.org/citations/25083991http://purl.uniprot.org/core/author"Goh B.C."xsd:string
▶